Current Issues of Pharmacy and Medical Sciences

Fetuin-A in patients with metabolic syndrome

Current Issues in Pharmacy and Medical Sciences Vol. 26, No. 3, Pages 305-308


1 Department of Endocrinology, Medical University, Lublin, Poland
2 Department of Biochemical Diagnostics, Chair of Laboratory Diagnostics, Medical University, Lublin, Poland
3 Department of Mathematics and Medical Biostatistics, Medical University, Lublin, Poland
4 Department of Cardiology, Medical University, Lublin, Poland

DOI: 10.12923/j.2084-980X/26.3/a.14



Metabolic syndrome is a common disorder the prevalence of which is estimated to be about 20% in Polish adult population. Abdominal obesity and insulin resistance are important pathogenetic factors. Metabolic syndrome plays a role as a risk factor for type 2 diabetes and cardiovascular disease. Fetuin-A is a multifunctional plasma glycoprotein. It is a physiological inhibitor of  insulin receptor tyrosine kinase and thus associated with insulin resistance, metabolic syndrome and an increased risk for type 2 diabetes. The study was conducted in 62 patients with metabolic syndrome (34F and 28M) aged 35-83. In 47 persons type 2 diabetes was a component of metabolic syndrome, 62% of diabetics had coronary artery disease as a macrovascular complication. Determinations of biochemical parameters and anthropometric measurements were performed in the studied group. We analysed a relationship between serum fetuin-A concentration and components of metabolic syndrome and total cholesterol, LDL-cholesterol, HbA1C, BMI as well. Diabetics had lower fetuin-A concentrations than patients without diabetes (0.550 g/l vs 0.600 g/l). Fetuin-A levels in patients with diabetes and coronary artery disease were significantly lower (0.535 g/l) than in those without macrovascular complications (0.590 g/l) (Z=1.969; p=0.048). Furthermore the correlation between fetuin-A serum
concentration and fasting plasma glucose, LDL-cholesterol and triglycerides levels were observed. Patients with higher fasting glucose had lower fetuin-A levels. However, fetuin-A concentration was positive correlated with LDL-cholesterol and triglycerides levels. No association between fetuin-A and waist circumference, blood pressure, HDL-cholesterol, HbA1C and BMI were found. In summary, serum fetuin-A level has a correlation with some components of metabolic syndrome. We concluded that fetuin-A could be used not only as a marker, but also plays some role in pathogenesis of metabolic syndrome, type 2 diabetes and higher risk of cardiovascular disease.

Files to download


fetuin-A, metabolic syndrome, type 2 diabetes


  1. Brix J.M., Stingl H., Hollerl F. et al. Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. J. Clin. Endocrinol. Metab., 95, 4877, 2010.
  2. Erdmann J., Salmhofer H., Knauß A. et al. Relationship of fetuin-A levels to weight-dependent insulin resistence and type 2 diabetes mellitus. Regul. Pept., 178, 6, 2012.
  3. Ismail N.A., Ragab S., Abd El Dayem S.M. et al. Fetuin A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch. Med. Sci., 5, 826, 2012.
  4. Ix J.H., Shlipak M.G., Brandenburg V.M. et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation, 113, 1760, 2006.
  5. Ix J.H., Wassel C.L., Kanaya A.M. et al. Fetuin-A and incident diabetes mellitus in older persons. JAMA, 300, 182, 2008.
  6. Jahnen-Dechent W., Heiss A., Schäfer C. et al. Fetuin-A regulation of calcified matrix metabolism. Circ. Res., 108, 1494, 2011.
  7. Kaushik S.V., Plaisance E.P., Kim T. et al. Extended-release niacin decreases serum fetuin-A concentrations in indivuduals with metabolic syndrome. Diabetes. Metab. Res. Rev., 25, 427, 2009.
  8. Reinehr T., Roth C.L. Fetuin-A and its relation to metabolit syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab., 93, 4479, 2008.
  9. Sieradzki J. (2010). Cukrzyca i zespół metaboliczny. In: Choroby wewnętrzne. Stan wiedzy na rok 2010. Szczeklik A. (editor). Kraków: Medycyna Praktyczna; p. 1283.
  10. Singh M., Sharma P.K., Garg V.K. et al. Role of fetuin-A in atherosclerosis associated with diabetic patients. J. Pharm. Pharmacol., 64, 1703, 2012.
  11. Stefan N., Fritsche A., Weikert C. et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes, 57, 2762, 2008.
  12. Stefan N., Hennige A.M., Steiger H. et al. α2-Heremans-Schmid Glycoprotein/Fetuin-A is associated with insulin resistence and fat accumulation in the liver in humans. Diabetes Care, 29, 853, 2006.
  13. Vörös K., Gráf L. Jr., Prohászka Z. et al. Serum fetuin-A inmetabolic and inflammatory pathways in patients with myocardial infarction. Eur. J. Clin. Invest., 41, 703, 2011.
  14. Wojtysiak-Duma B., Malecha Jędraszek A., Burska A. et al. Serum fetuiny-A levels in patients with type 2 diabetes mellitus. Ann. UMCS Sect. DDD, 2, 93, 2010.
  15. Xu Y., Xu M., Bi Y. et al. Serum fetuin-a is corretaled with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis, 216, 180, 2011.
prev next



April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30